proline/neoplasms

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT [Not applicable] BACKGROUND The tumor suppressor p53 (protein expressed from TP53) has been shown to be downregulated in numerous cancers. The p53 protein exerts its tumor suppressive function acting

BACKGROUND OF THE INVENTION The present invention relates to a pharmaceutical composition comprising of proline or proline derivatives or their salts, esters, isomers or prodrugs together with an anti-cancer ligand, preferably an antibody directed to a tumour antigen. The invention is also directed

INTRODUCTION The invention relates to a combination of therapeutic agents, comprising as essential components: (A) cis-4-hydroxy-L-proline and (B) N-methyl-cis-4-hydroxy-L-proline, or their pharmacologically compatible derivatives or precursors, for use as a therapeutic agent, particularly for

FIELD OF THE INVENTION The invention relates to a new aprepritant compositions and crystalline compounds containing aprepitant. More particularly, the invention relates to solvated aprepitant L-proline solvate compositions, aprepitant L-proline solvate cocrystals, therapeutic uses of the aprepitant

FIELD OF THE INVENTION The invention relates to a new aprepitant composition and a crystalline compound containing aprepitant, more particularly, the invention relates to an aprepitant L-proline composition, an aprepitant L-proline cocrystal, therapeutic uses of the aprepitant L-proline or the

Till now chemotherapeutic treatment of cancer, especially carcinomas, is not satisfying as the therapeutic effects are very limited and the side effects are very severe. The latter is due to the fact that highly toxic substances are used, which damage not only the cancer cells but the other cells of

This application is a U.S. national stage of International Application No. PCT/JP2008/063235 filed Jul. 24, 2008. CROSS-REFERENCE OF RELATED APPLICATION This patent application claims a priority based on a prior Japanese Patent Application, Japanese Patent Application No. 193328/2007 (filing date:

FILED OF THE INVENTION The present invention relates to the use of catechin compounds in combination with other dietary constituents in inhibiting matrix-metalloproteinases. More particularly, the present invention relates to the use of a composition comprising catechin, ascorbic acid, lysine and

CROSS REFERENCE TO RELATED APPLICATIONS This application is a U.S. National Stage Application filed under 35 U.S.C. .sctn.371 and claims priority to International Application No. PCT/EP2009/052883, filed Mar. 11, 2009, which application claims priority to Great Britain Application No. 0804496.8,

FIELD OF THE INVENTION The present invention relates to a nutrient pharmaceutical formulation and its use for the treatment of cancer. More specifically, the present invention relates to polyphenol containing pharmaceutical formulations having an effective amount of polyphenols for the treatment of

FUNDING Work described herein was funded by the National Institutes of Health, the Medical Research Council of Canada and the National Cancer Institute. BACKGROUND Wilms' tumor (WT) is an embryonal malignancy of the kidney which affects approximately 1 in 10,000 infants and young children.

FUNDING Work described herein was funded by the National Institutes of Health, the Medical Research Council of Canada and the National Cancer Institute. BACKGROUND Wilms' tumor (WT) is an embryonal malignancy of the kidney which affects approximately 1 in 10,000 infants and young children.

FUNDING Work described herein was funded by the National Institutes of Health, the Medical Research Council of Canada and the National Cancer Institute. BACKGROUND Wilms' tumor (WT) is an embryonal malignancy of the kidney which affects approximately 1 in 10,000 infants and young children.

BACKGROUND Wilm's tumor (WT) is an embryonal malignacy of the kidney which affects approximately 1 in 10,000 infants and young children. Matsunaga, Human Genetics, 57: 231-246 (1981). The molecular basis of Wilms' tumor is not well understood. A subset of Wilms' tumor cases (approximately 2%) occur

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a national phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/EP2014/050330 filed 9 Jan. 2014, which claims priority to European Patent Application No. 13150974.7 filed 11 Jan. 2013. The entire contents of each